Ryan Cross

2.5k total citations
20 papers, 84 citations indexed

About

Ryan Cross is a scholar working on Molecular Biology, Infectious Diseases and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Ryan Cross has authored 20 papers receiving a total of 84 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 5 papers in Infectious Diseases and 2 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Ryan Cross's work include CRISPR and Genetic Engineering (6 papers), SARS-CoV-2 and COVID-19 Research (5 papers) and Biotechnology and Related Fields (2 papers). Ryan Cross is often cited by papers focused on CRISPR and Genetic Engineering (6 papers), SARS-CoV-2 and COVID-19 Research (5 papers) and Biotechnology and Related Fields (2 papers). Ryan Cross collaborates with scholars based in United Kingdom and Hong Kong. Ryan Cross's co-authors include Saul Hillman and has published in prestigious journals such as Frontiers in Psychology, Chemical & Engineering News and C&EN Global Enterprise.

In The Last Decade

Ryan Cross

18 papers receiving 83 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ryan Cross United Kingdom 4 58 9 8 7 6 20 84
Yingying Lin China 4 47 0.8× 11 1.2× 6 0.8× 2 0.3× 12 2.0× 10 82
Angela H. Beckett United Kingdom 5 69 1.2× 4 0.4× 5 0.6× 2 0.3× 7 1.2× 11 126
Gisela Pittner Austria 6 49 0.8× 5 0.6× 5 0.6× 2 0.3× 4 0.7× 11 259
J Abu Qatar 4 32 0.6× 4 0.4× 14 1.8× 2 0.3× 17 2.8× 4 119
Dipanjali Sinha India 4 97 1.7× 14 1.6× 11 1.4× 4 0.6× 1 0.2× 4 109
Desiree‐Faye Kaixin Toh Singapore 10 317 5.5× 10 1.1× 14 1.8× 18 2.6× 12 2.0× 12 337
Kathryn Tunyasuvunakool United Kingdom 5 60 1.0× 3 0.3× 4 0.5× 3 0.4× 3 0.5× 5 93
Yanxiang Huang China 6 46 0.8× 10 1.1× 7 0.9× 2 0.3× 11 129
Anne Labarre Canada 4 46 0.8× 37 4.1× 7 0.9× 12 2.0× 4 108
Isaac Han United States 5 78 1.3× 11 1.2× 2 0.3× 3 0.4× 4 0.7× 5 100

Countries citing papers authored by Ryan Cross

Since Specialization
Citations

This map shows the geographic impact of Ryan Cross's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryan Cross with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryan Cross more than expected).

Fields of papers citing papers by Ryan Cross

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryan Cross. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryan Cross. The network helps show where Ryan Cross may publish in the future.

Co-authorship network of co-authors of Ryan Cross

This figure shows the co-authorship network connecting the top 25 collaborators of Ryan Cross. A scholar is included among the top collaborators of Ryan Cross based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ryan Cross. Ryan Cross is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hillman, Saul, et al.. (2025). Preliminary findings on psychometric properties of the adolescent story stem profile. Frontiers in Psychology. 16. 1478372–1478372. 1 indexed citations
2.
Cross, Ryan. (2021). Omicron puts scientists on red alert. C&EN Global Enterprise. 99(44). 6–6. 2 indexed citations
3.
Cross, Ryan. (2021). Without these lipid shells, there would be no mRNA vaccines for COVID-19. Chemical & Engineering News. 16–19. 19 indexed citations
4.
Cross, Ryan. (2021). Lilly taps ProQR for RNA editing. C&EN Global Enterprise. 99(34). 19–19. 2 indexed citations
5.
Cross, Ryan. (2020). Will the coronavirus help mRNA and DNA vaccines prove their worth?. C&EN Global Enterprise. 98(14). 26–29.
6.
Cross, Ryan. (2020). FDA authorizes COVID-19 antibody therapy. C&EN Global Enterprise. 98(44). 15–15. 2 indexed citations
7.
Cross, Ryan. (2020). Can adenoviral vectors overcome a checkered past to win the COVID-19 vaccine race?. C&EN Global Enterprise. 98(19). 20–23. 1 indexed citations
8.
Cross, Ryan. (2020). Moderna says COVID-19 vaccine is 94.5% effective in preliminary analysis. Chemical & Engineering News. 4–5. 1 indexed citations
9.
Cross, Ryan. (2019). PKU, a once-neglected disease, is now a proving ground for new drugs. C&EN Global Enterprise. 97(27). 24–30. 2 indexed citations
10.
Cross, Ryan. (2019). A search-and-replace gene-editing tool. C&EN Global Enterprise. 97(42). 3–3. 1 indexed citations
11.
Cross, Ryan. (2019). Introducing CRISPR 3.0. C&EN Global Enterprise. 97(47). 38–38. 1 indexed citations
12.
Cross, Ryan. (2019). Gene-editing start-up Trucode launches. C&EN Global Enterprise. 97(36). 10–10. 1 indexed citations
13.
Cross, Ryan. (2019). Epitranscriptomics: The new RNA code and the race to drug it. C&EN Global Enterprise. 97(7). 34–39. 7 indexed citations
14.
Cross, Ryan. (2019). Watch out, CRISPR. The RNA-editing race is on. C&EN Global Enterprise. 97(12). 20–21. 2 indexed citations
15.
Cross, Ryan. (2018). Exosomes, nature’s drug delivery fleet. C&EN Global Enterprise. 96(31). 22–24. 3 indexed citations
16.
Cross, Ryan. (2018). CRISPR comes to the clinic. C&EN Global Enterprise. 96(2). 18–19. 1 indexed citations
17.
Cross, Ryan. (2018). Can mRNA disrupt the drug industry?. C&EN Global Enterprise. 96(35). 35–40. 6 indexed citations
18.
Cross, Ryan. (2017). CRISPR’s breakthrough problem. C&EN Global Enterprise. 95(7). 28–33. 30 indexed citations
19.
Cross, Ryan. (2017). The RNA drug hunters. C&EN Global Enterprise. 95(47). 16–18. 2 indexed citations
20.
Cross, Ryan. (2016). CRISPR edits sickle cell mutation. C&EN Global Enterprise. 94(41). 5–5.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yingying Lin Breakdown of academic impact, for papers by Angela H. Beckett Breakdown of academic impact, for papers by Gisela Pittner Breakdown of academic impact, for papers by J Abu Breakdown of academic impact, for papers by Dipanjali Sinha Breakdown of academic impact, for papers by Desiree‐Faye Kaixin Toh Breakdown of academic impact, for papers by Kathryn Tunyasuvunakool Breakdown of academic impact, for papers by Yanxiang Huang Breakdown of academic impact, for papers by Anne Labarre Breakdown of academic impact, for papers by Isaac Han
Rankless by CCL
2026